
|Videos|October 10, 2017
The Current Role of Checkpoint Inhibitors in Head and Neck Cancer
Author(s)Everett E. Vokes, MD
Everett E. Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, Physician-in-Chief, University of Chicago Medicine and Biological Sciences, Chair, Department of Medicine, discusses the current role of checkpoint inhibitors for the treatment of head and neck cancer during the ESMO 2017 Congress.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Tentative Approval to New Cabozantinib Capsule Formulation
2
In Squamous NSCLC, Cemiplimab Data Pulled the Room Away From Dual Checkpoint Blockade
3
FDA Clears Rituximab Biosimilar, Expanding Options for B-Cell Malignancies
4
Real-World Analysis Explores GLP-1 Use and Overall Survival
5










































